global commercial potential

Bird Flu Vaccine
Our new Bird Flu trial vaccine under development is being evaluated to optimise the dose, administration timing and method. This work is being performed at contracted laboratories in Victoria. Once these evaluations have been completed our vaccine will be tested in the high security area of CSIRO’s animal health centre. CSIRO has indicated that its trial scheduling should have these trials completed during calendar year 2005.
The Bird Flu vaccine remains a high priority for Imugene, particularly given the catastrophic potential and warnings of imminence by organisations such as the World Health Organisation. An effective vaccine for poultry will have substantial global commercial potential and Imugene is determined to capture that market.